Clinical Trial

Study to Evaluate Safety and Efficacy of EG-301 in Patients With Nonfocal Geographic Atrophy Secondary to Dry-AMD

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a parallel, randomized, open-label, controlled study to evaluate the efficacy and safety of oral EG-301 in patients with intermediate non-exudative (dry) age-related macular degeneration (dAMD). Ninety patients will be randomly allocated in a 2:1 ratio to one of two treatment arms for at least 6 months duration. The two treatment arms are: 1. AREDS2 supplements (Control Group, N=30) 2. AREDS2 supplements plus EG-DPMP-01 150 mg daily (Experimental Group, N=60)
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-12-10; most recent amendment 2025-12-02.
Trial Details
NCT Number NCT05170048
Lead Sponsor Evergreen Therapeutics, Inc.
Conditions Non-Exudative (Dry) Age-related Macular Degeneration (dAMD)
Enrollment 90 participants
Start Date 2026-06
Primary Completion 2028-06 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2025-12-08